Neuromuscular disorder in which autoantibodies cause a decrease in the presynaptic release of acetylcholine.
A disorder of the presynaptic, neuromuscular junction character characterized by muscle weakness.
It has an estimated incidence of 0.4 cases per million population.
The syndrome may be paraneoplastic, or unrelated to tumors and is typically manifested by progressive proximal weakness often starting in the legs, alongside autonomic symptoms, such as dry mouth and orthostatic hypotension,
Myasthenic syndrome affecting about 3% of patients with small cell lung cancer.
A rare autoimmune disease that causes the debilitating muscle weakness.
Patients generate antibodies against synaptic proteins at the neuromuscular junction, decreasing the release of the neurotransmitter acetylcholine and impairs muscle contraction.
The presence of autoantibodies that target presynaptic VGCCs (voltage gated calcium channels).
Antibodies inhibit the release of neurotransmitters at the neuromuscular junction, which intern causes muscle weakness, particularly in the proximal leg muscles.
60% of patients have a small cell cancer of the lung.
Cases have been reported with breast, ovarian, and Thymic cancers.
An autoimmune disorder that damages calcium channels on nerve endings, leading to reduction in acetylcholine release.
Patients have impaired muscle contractions and weakness.
The process is manifested by progressive proximal weakness, often starting in the legs, alongside autonomic symptoms, such as dry mouth and orthostatic hypotension.
Nerve conduction studies typically show low amplitude compound muscle action potentials with normal velocity.
A decrement in amplitude during repetitive nurse stimulation has a sensitivity of approximately 90% for the syndrome.
The Lamber-Eaton syndrome affects the presynaptic, neuromuscular junction, rather than the postsynaptic neuromuscular junction abnormalities seen with myasthenia gravis.
Deep tendon reflexes are typically reduced or absent.
The condition often occurs in patients with cancer, especially small cell lung cancer.
Estimate 800 people in the US have Eaten Lambert syndrome and up to 170 new cases are diagnosed annually.
Amifampridine, marketed as Firdapse, is an oral potassium channel blocker and is approved for treatment of this syndrome.
Amifampridine increases synaptic acetylcholine concentrations by blocking potassium channels on nerve endings: it enhances acetylcholine release.
Common side effects of Amifampridine are paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, muscle spasms, or seizures.